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Introduction
Antisense oligonucleotides (ASOs) are modified nucleic
acids that alter gene expression in cells by binding target
mRNA in a sequence-specific manner. ASO binding can
trigger degradation or alter processing of mRNA. Potential
advantages of this class of therapeutic include specificity
(from base pairing), amplification of effect (one ASO can
catalyse the degradation/processing of many mRNAs), and
reversibility (in contrast to gene therapies acting on DNA).
Many neurodegenerative diseases have either a direct
genetic cause or a phenotype that is modified by genetic
variation making them ideal candidates for ASO thera-
peutics. In practice, developing effective ASOs for neuro-
logical disease has been difficult: targeting to the
appropriate part of the central nervous system (CNS) is
problematic and early ASOs had short half-lives and sig-
nificant inflammatory side effects. However, advances in
ASO chemistry over the last 20 years have improved the
pharmacodynamic, pharmacokinetic, and side-effect pro-
files of these drugs which are now being trialled in a range
of conditions, with promising early results.
This month’s journal club examines three papers
involving ASO therapeutics in neurodegeneration. The first
two papers look at amyotrophic lateral sclerosis (ALS): one
using cell/animal models to show the utility of ASOs and
the other demonstrating the safety of intrathecal ASOs in
humans. The third paper reports the exciting success of
ASO therapy in treating spinal muscular atrophy (SMA).
Poly(GP) proteins are a useful pharmacodynamic
marker for C9ORF72-associated amyotrophic
lateral sclerosis
The most common known mutation associated with ALS/
frontotemporal dementia (FTD) is a G4C2 hexanucleotide
DNA repeat expansion in the non-coding region of
C9ORF72, accounting for at least 10% of all ALS/FTD (up
to 40% of familial cases, at least 10% of sporadic cases).
Sense and antisense transcripts of the repeat are produced
in cells and can be translated in each of the three possible
frames to produce six repeating dipeptides. Both RNA and
protein derived from the repeat have been implicated in
pathogenesis, but exact mechanisms remain unclear.
This paper investigated the utility of one of these
repeating dipeptides, poly(GP), as a pharmacodynamic
marker for C9ORF72-associated ALS. It demonstrates that
poly(GP) is detectable in CSF of patients with G4C2 repeat
expansion, whether symptomatic or not, and that CSF
poly(GP) concentration is stable in individuals over time
periods of up to 22 months. There was no significant
association between poly(GP) and age at onset or pro-
gression of disease. Lymphoblastoid and induced pluripo-
tent stem cell-derived neuronal lines from patients with
C9ORF72-related ALS produced poly(GP) in culture, with
intracellular and extracellular concentrations correlated.
Treatment with ASOs against G4C2 repeats reduced both
repeat-containing RNA foci and poly(GP) concentrations
in cells. Finally, a G4C2 repeat-specific ASO was delivered
through a single bolus injection to the right ventricle of the
brains of transgenic mice expressing (G4C2)66 as a model
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of C9ORF72-associated ALS. Mice were injected at
4 months of age, prior to the onset of pathology, and
examined at 6 months of age. Repeat-containing RNA
concentrations were reduced by approximately 50% with
no effect on endogenous C9orf72 mRNA. Poly(GP) con-
centrations in CSF and brain were correlated and both were
significantly reduced following ASO treatment. RNA foci
and poly(GP)-containing inclusions were reduced in the
motor cortices of ASO-treated mice.
Comment. In the specific context of C9ORF72-associ-
ated ALS/FTD, poly(GP) in CSF reflects transcription and
translation of the repeat. However, poly(GP) is not a good
biomarker of ALS/FTD: it was found in patients whether
symptomatic or not, its presence did not correlate with
disease onset or progression, and its concentration did not
correlate with disease severity. As expected, ASOs against
the G4C2 repeat reduced mRNA and poly(GP) concentra-
tions in cells and mice, but the utility of poly(GP) as a
pharmacodynamic marker may be clouded by its produc-
tion from both sense and antisense transcripts of the repeat.
Gendron TF et al (2017) Sci Transl Med 9:eaai7866
An antisense oligonucleotide against SOD1
delivered intrathecally for patients with SOD1
familial amyotrophic lateral sclerosis: a phase 1,
randomised, first-in-man study
Approximately 10–20% of familial ALS (and 1–2% of
sporadic ALS) is caused by a toxic gain-of-function
mutation in SOD1 leading to motor neuron loss by a poorly
understood mechanism. This paper reported a first-in-man,
randomised, double-blinded, placebo-controlled phase I
trial of intrathecal ASO against SOD1 mRNA (both wild
type and mutant). Patients (n = 21) with a family history
of ALS and carrying a documented heterozygous mutation
in SOD1 were enrolled into four cohorts of eight (some
were re-enrolled) and treated with a single, small volume
(0.25 ml) intrathecal administration of SOD1 ASO or pla-
cebo over 11.5 h via a lumbar intraspinal catheter.
Sequential cohorts received increasing doses of ASO.
Although 84% of patients reported adverse events, these
were mild, self-limiting, and mostly related to lumbar
puncture (headache and back pain). There was no signifi-
cant difference in adverse events either between treatment
and placebo groups or between cohorts. No adverse reac-
tions related to the study drug were reported. At higher
ASO doses, clearance into the plasma was detected,
peaking at 12 h post-administration. One patient died
during the study (from ALS): post-mortem examination
revealed study drug throughout the spinal cord with a
gradient from lumbar to cervical.
Comment. This study has demonstrated that intrathecal
ASO delivery is both practical and safe in patients. Side
effects were mild and predictable, and related to the lumbar
puncture procedure rather than the study drug. There was
some clearance of drug into the plasma at higher doses
which has potential safety implications, since homozygous
Sod1 knockout mice develop multiple pathologies,
including hepatic cancer and motor neuropathy. Although
the ASO is likely only to lower SOD1 protein levels (rather
than ablating them), the long-term effects of protein-low-
ering need investigating, particularly as the ASO is not
specific for mutant over wild-type SOD1.
Miller TM et al (2013) Lancet Neurol 12:435–442
Treatment of infantile-onset spinal muscular
atrophy with nusinersen: a phase 2, open-label,
dose-escalation study
Spinal muscular atrophy (SMA) is a devastating motor
neuron disease that usually presents in childhood and
affects about 1 in 11,000. The most severe, infantile-onset,
form of SMA (60% of all cases) presents before 6 months
of age with profound muscle weakness that typically leads
to early ventilator dependence and a life expectancy of less
than 2 years. There have been no disease-modifying
treatments available. SMA is caused by a loss-of-function
mutation in the Survival Motor Neuron 1 (SMN1) gene that
leads to reliance on a nearby related gene, SMN2. SMN2
differs only by 11 nucleotides from SMN1 but, crucially,
has a splice site enhancer mutation that means only
10–25% of its transcripts contain exon 7 and can generate
full-length functional SMN protein. The remaining tran-
scripts are degraded. The severity of SMA is related to
SMN2 copy number and hence its ability to compensate for
defective SMN1. The ASO trialled here (‘nusinersen’)
binds specifically to SMN2 mRNA and modulates splicing,
such that exon 7 is included in processed transcripts and
more functional SMN2 protein is produced.
Twenty infants (between 3 weeks and 6 months of age)
with SMA were treated with a loading and maintenance
regimen of intrathecal nusinersen injections and followed
for up to 32 months. The procedure was well tolerated and
the drug safe, although all participants experienced mild–
moderate adverse events. These were all deemed related to
the natural history of SMA rather than drug administration.
Significant improvements in developmental motor mile-
stones, motor function, and ventilation-free survival (65 vs.
15% at 24 months of age) were recorded following treat-
ment with nusinersen. Plasma concentrations peaked 1 h
after administration and were dose dependent. Three
infants died during the study from SMA: post-mortem
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examination showed that nusinersen was widely distributed
throughout the CNS, including in deep brain structures, and
also found in peripheral tissues such as liver and kidney.
Analysis of thoracic spinal cord showed that nusinersen
treatment was associated with dramatic increases in the
amount of functional SMN2 mRNA (21 vs. 57%) and SMN
protein in motor neurons.
Comment. This study has provided the first direct evi-
dence for antisense efficacy in the human CNS. Intrathecal
injections of nusinersen were tolerated and safe, and
delivered drug to target CNS tissues, where expected
mRNA and protein effects were observed. Drug adminis-
tration was associated with dramatic clinical improve-
ments, and hence, nusinersen was taken forward to a phase
III trial (ENDEAR) which was itself stopped after an
interim analysis showed that 40% of patients in the treat-
ment arm showed significant motor improvements com-
pared to 0% in the placebo arm. Patients have now been
enrolled into an ongoing open-label study (SHINE) which
is running until 2020. Nusinersen has recently received
FDA and EMA approval for the treatment of SMA (De-
cember 2016 and April 2017 respectively).
Finkel RS et al (2016) Lancet 388:3017–3026
Conclusion
Intrathecal ASOs can be delivered safely in humans and
induce predictable changes in gene expression in the CNS.
The encouraging data relating to SMA suggest that ASOs
can modify disease course in certain circumstances.
However, we should be cautious when extrapolating from
these results: the studies are small, the pathogenesis of
SMA unusual, the follow-up time short, and the implica-
tions of widespread CNS and systemic ASO distribution
unknown. In addition, ASOs targeting dominant-negative
conditions are often not allele-specific, and therefore, the
effects of targeting mutant and wild-type mRNAs must be
carefully assessed in individual diseases.
The current trials of intrathecal ASOs in Huntington’s
disease and Alzheimer’s disease, as well as ongoing studies
in SMA, will provide greater understanding of these ther-
apeutics. If results are positive, the emergence of ASOs
could mark a paradigm shift in how clinicians treat
genetically mediated neurodegenerative conditions.
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